Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.
Ph.D. of Translational Medicine, Chair of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.
Cardiovasc Diabetol. 2021 Jan 11;20(1):17. doi: 10.1186/s12933-021-01213-w.
Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for patients with type 2 diabetes (T2D), in particular for older people. Newer glucose-lowering medications have generated some optimism on the possibility to influence the natural history of cardiorenal complications of T2D. This review summarizes work in the area of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) treatment and prevention of cardiorenal complications in patients with T2D (major adverse cardiovascular events, hospitalization for heart failure, kidney outcomes), with a particular emphasis on the effect of age, the role of primary versus secondary prevention and the possible extension of their cardiorenal benefits to the entire class of SGLT-2i.
因 2 型糖尿病（T2D）的主要并发症（包括心肌梗死、中风、下肢截肢和终末期肾病）而住院的情况日益增多，给患者带来了巨大的健康负担，尤其是老年人。新型降糖药物的出现让人们对可能影响 T2D 的心脏和肾脏并发症的自然病程产生了一些乐观情绪。本综述总结了钠-葡萄糖共转运蛋白 2 抑制剂（SGLT-2i）在 T2D 患者中的心脏和肾脏并发症治疗和预防方面的工作（主要不良心血管事件、心力衰竭住院、肾脏结局），特别强调了年龄的影响、一级预防和二级预防的作用，以及它们的心脏和肾脏获益可能扩展到整个 SGLT-2i 类药物。
